Longevity Fund

Longevity Fund Longevity Fund, founded in 2014 by Laura Deming. who joined MIT's aging biology lab at age 14. is a San Francisco-based pioneer that helped establish longevity therapeutics as a venture category. With $37M across three funds, the firm invests at seed and Series A in senolytics, aging biology, and healthspan-extending therapeutics. Portfolio companies including Unity Biotechnology, Precision Biosciences, and Loyal (which secured the first FDA healthspan endpoint concurrence) have